Patent · US Active

Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides

US12097242B2 · kind B2 · utility

0Cited by

208References

26Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Gene M. Dubowchik · Middlefield, US
Olafur S. Gudmundsson · Princeton Colonial Park, US
Xiaojun Han · Cheshire, US
R. Michael Lawrence · Yardley, US
Dasa Lipovsek · Pepperell, US
Cort S. Madsen · Plainsboro, US
Claudio Mapelli · Princeton, US
Paul E. Morin · Pennington, US
Michael C. Myers · Newtown, US

Key dates

Filing date	Apr 15, 2022
Grant date	Sep 24, 2024
Priority date	—
Expiry date	Jun 29, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P9/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.